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Abstract
Introduction:
Generating optimal control algorithms for an artificial pancreas is an intensively researched problem. 
The available models are all nonlinear and rather complex. Model predictive control or run-to-run-based 
methodologies have proven to be efficient solutions for individualized treatment of type 1 diabetes mellitus 
(T1DM). However, the controller has to ensure safety and stability under all circumstances. Robust control 
methods seek to provide this safety and guarantee to handle even the worst-case situations and, hence, 
to generalize and complement results obtained by individualized control algorithms.
Methods:
Modern robust (e.g., Hinf) control is a linear model-based methodology that we have combined with the 
nonlinear model-based linear parameter varying technique. The control algorithm was designed on the 
high-complexity modified nonlinear glucose–insulin model of Sorensen, and it was compared step-by-step 
with linear model-based Hinf control results published in the literature. The applicability of the developed 
algorithm was tested first on a control cohort of 10 healthy persons’ oral glucose tolerance test results and 
then on a large meal absorption profile adapted from the literature. In the latter case, two preliminary 
virtual patients were generated based on 1–1 week real continuous glucose monitor measurements.
Results:
We have found that the algorithm avoids hypoglycemia (not caused by physical activity or stress) independently 
from the considered absorption profiles.
Conclusion:
Use of hard constraints proved their efficiency in fitting blood glucose level within a defined interval. However, 
in the future, more data of different T1DM patients will be collected and tested, including dynamic absorption 
model and in silico tests on validated simulators.
J Diabetes Sci Technol 2013;7(3):708–716
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Introduction
According to data provided by the World Health Organization, the diabetes population is predicted to double 
from 2000 to 2030,1 and the trend is maintained in a 2010 prognosis as well.2 Regarding type 1 diabetes mellitus (T1DM), 
the statistics of the International Diabetes Federation show that the European Region has the highest number and 
the highest incidence rate of T1DM in children compared with any other region worldwide.3 Uncontrolled T1DM 
(characterized by complete pancreatic β-cell insufficiency) results in acute events and chronic diseases, e.g., cardio-
vascular disease and kidney disease.4
Technological advances have enabled development of (i) continuous glucose monitors (CGMs) for subcutaneous 
measurement of glucose concentration and (ii) insulin pumps for subcutaneous delivery of insulin.5 Sensor-augmented 
pump therapy seems to improve glycemic control compared with traditional therapeutic schemes.6 Furthermore, 
automatic regulation of the glucose profile using a controller that closes the loop between CGM and pump will make 
the realization of an artificial pancreas (AP) feasible.7–9
To design an appropriate control, an adequate model is necessary. Different mathematical models of the human blood 
glucose system have appeared.5 The minimal model10 proved to be the simplest one, but a lot of components of the 
glucose–insulin interaction were neglected in its formulation. Therefore, other general but more complicated models 
emerged.11–14
Although different control algorithms have been proposed in the literature,5,8,15 only four main control strategies 
have been used for AP prototype systems: proportional-integral-derivative-based controllers,16 model predictive 
control (MPC),17–19 run-to-run,20 and fuzzy logic.21 The majority of the mentioned algorithms are able to achieve 
nocturnal glucose regulation. The MPC-based approaches resulted in less hypoglycemic events and increased time 
in normoglycemia, while the run-to-run- and fuzzy-logic-based controllers had good performance during closed loop.
Due to insulin sensitivity differences and patient variability, hard constraints should also be beneficial in handling 
model uncertainties.12,22 Modern robust control theory is suitable for these purposes23 by maintaining stability and 
performance level despite uncertainties in system dynamics. Although they represent linear control methods providing 
systematic design procedures of robust controllers, extension into nonlinear cases is an actively researched topic 
nowadays. A promising candidate is represented by the linear parameter varying (LPV) methodology, where—by 
adequately choosing variables—the nonlinearity can be hidden.24
The aim of this article is to briefly summarize the developed nonlinear model-based LPV robust controller and to prove 
its applicability and robustness on different preliminary scenarios taken into account.
Methods
Linear Parameter Varying System Definition
The LPV system is a class of nonlinear systems, where the parameter could be an arbitrary time-varying, piecewise-
continuous, vector-valued function denoted by ρ(t), defined on a compact set P. In order to evaluate the system, 
the parameter trajectory is requested to be known either by measurement or by computation.24–26
An nth-order LPV system can be written in the form of
ẋ(t) = A(ρ)x(t) + B(ρ)u(t)
y(t) = C(ρ)x(t) + D(ρ)u(t)
 ,                                                        (1)
where A = RS→Rn×n, B = RS → Rn×nu, C = RS→Rny×n, and D = RS→Rny×nu are continuous functions.27
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Hence, LPV systems provide a model paradigm that goes beyond the classical representation of nonlinear and linear 
systems.28 Basically, LPV systems can be seen as an extension of linear time invariant (LTI) systems, where the 
relations are considered to be linear, but model parameters are assumed to be functions of a time-varying signal 
that is available for measurement. By choosing parameter variables, the system’s nonlinearity can be hidden, as the 
measured parameters describe the whole working domain of the designed controller. This methodology is used in 
different control solutions.29
Linear Parameter Varying Modeling of the Type 1 Diabetes Mellitus Problem
There are different descriptions of the LPV systems.28 In the affine description possibility, a part of the x(t) states are 
equal with the ρ(t) parameters.
The control problem was considered on the modified version of the 19th-order Sorensen model,12 which is one of the 
most complex glucose–insulin models in the literature. The compartmental structure of the model is presented in 
Figure 1, while its detailed description can be found elsewhere.24
Figure 1. Compartmental representation of the modified Sorensen 
model.12
However, due to the complexity of the modified Sorensen 
model, it is difficult or nearly impossible to capture the 
dynamics with affine-type LPV representation. Hence, 
polytopic representation was investigated, in which case 
the validity of the model is caught inside a polytopic 
region, and the model is built up by a linear combination 
of the linearized models derived in each polytopic point:
Si = 
Ai     Bi
Ci     Di
⎡
⎢
⎣
⎤
⎥
⎦
The polytopic LPV model can be thought of as a set 
of linear models on a vertex (a convex envelope of LTI 
systems), where the grid points of the description are 
LTI systems. The LPV polytopic model is valid only in 
a restricted domain, characterized by the range of the 
polytope.24,25
The validity of the modified Sorensen model was captured 
by a set of 48 points,24,26 where, in each point, the system 
was linearized. The created LPV model was proven to fit 
the original system.26
The Linear-Parameter-Varying-Based Robust Controller
The LPV-based robust controller was developed to minimize the meal disturbance level over the performance output 
for all possible variation of the parameter within the created polytope:24,25
min G  = min  sup    sup
K K ρ ∈ Fp d  ≠ 0
zy1
d
 ,                                                   (2)
where d denotes the meal disturbance input and z describes the glucose variation. K represents the Hinf controller 
in question. FP denotes the set of all piecewise continuous functions mapping the positive real number set R+ (time) 
into the compact set P with a finite number of discontinuities in any interval. A priori information is injected to the 
controller throughout the augmentation of the nominal plant with extra dynamics, called weight functions.23
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The augmented system and the controller are presented in Figure 2. In order to reproduce the same results obtained 
by Parker and coauthors,12 the system was designed for the same absorption profile30 used by Parker and coauthors.12 
This step represented the starting point in our robust controller design procedure.24
Additionally, we have extended the constraint set of our robust structure with two multiplicative uncertainties weighting 
functions: output (see Wo in Figure 2), being considered negligible by Parker and coauthors12 (used as 1/10000), and 
input (see Wi and Wim in Figure 2). The reason for using output uncertainty is to reduce low-frequency glucose 
parameter errors (possible from CGM measurements) but also to consider neglected dynamics. Input multiplicative 
uncertainty was used on both glucose and insulin pathways of the model in order to model high-frequency dynamics. 
The weighting functions introduced were determined by sensitivity analysis using a similar procedure as Parker and 
coauthors.12 Moreover, worst-case meal disturbance was considered in our case [i.e., 60 g carbohydrate (CHO) intake)], 
whereas only 50 g CHO was considered by Parker and coauthors.12
Figure 2. The augmented system and the controller.24 The model is extended with the uncertainty weighting functions (Wi, Wim, Wm, Wo, Wp, Wn1, 
Wn2) and the uncertainty blocks (Δi, Δim, Δo). KL2 represents the controller, while the signals are as follows: disturbance (d), reference signal (r), 
control input (u), system outputs (y1, y2), weighting function outputs (ze, zy1), and inputs (n1, n2).
Results
During the Hinf control design and using γ-iteration 
algorithm, γ = 1.0096 solution was obtained (the tolerance 
for the algorithm was set to 0.01).24 The obtained value 
represents the upper limit of the robust performance 
criterion, which means that the formulated system 
requirements are quite severe. However, this could be an 
advantage in the validation process. Simulations on the 
reference value of Lehmann and Deutsch30 were tested 
and prove that hyperglycemia is avoided (Figure 3). 
Additionally, it should be highlighted that simulation 
results are better in the case of the original nonlinear 
system than on the LPV model, which is explained by the 
fact that the built polytopic region is more general than 
the validity interval of the original nonlinear process.24
Healthy Subjects’ Absorption Profile
In order to test other absorption profiles, we collected data 
from a cohort of 10 healthy subjects (7 females and 3 males), 
body mass index = 23.9 ± 3.9 kg/m2, age = 27.4 ± 2.5 years. 
Figure 3. The LPV-based robust controller in case of the original 
modified nonlinear Sorensen model12 (solid) and the considered 
polytopic region (dashed).24 Absorption CHO profile is taken from 
Lehmann and Deutsch.30
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Oral glucose tolerance tests (OGTTs) were performed using a strict protocol: subjects arrived all on foot to the 
measurement place, in fasting condition, and they had eaten the same dinner prior to the measurement. During 2 days, 
two different 60 g CHO meal types were given to them. First, an OGTT was performed on bread intake that was 
composed by 67% rapidly digestible starch (RDS), 30% slowly digestible starch (SDS), and 3% resistant starch (RS). 
On day 2, pasta was used for breakfast composed of 50% RDS, 46% SDS, and 4% RS. In both test scenarios, the meal 
had to be consumed within 15 min with 250 ml water.
The rationale for this protocol was twofold. By generating different meal profiles (on rapidly and slowly digestible 
CHO absorptions31), we investigated the validity of the created LPV region but also tested the robust controller. 
Namely, we built up the polytope region for the LPV model to capture the whole working domain of the original 
nonlinear model. However, due to the model’s characteristics, the created convex polytope is a more general region 
than the modified Sorensen’s model working domain. As a result, the designed linear-model-based robust controller 
works on a more general domain, and hence, using the same control input could produce a worse output than the 
original model.
These theoretical assumptions were verified for all the 10 tested healthy subjects. The LPV-based robust controller kept 
the output of the system (glucose) in the healthy 70–140 mg/dl interval and followed the measured OGTT profile.32 
Hence, the physiological background of the measured data set is covered by the constructed model. The differences of 
the glucose output between the LPV model and the original nonlinear model were maintained (similar to Figure 3), 
while the same insulin output has been calculated in both cases. Hence, it was demonstrated that, from an applicability 
point of view, there is no difference in insulin injection (as a control input) determination. Simulation results are 
shown in Figure 4 on one subject’s absorption profile from the measured cohort (for the two meal types separately).32
Figure 4. Simulation results of one subject’s absorption profiles from the measured healthy cohort. (A) Bread meal intake and (B) pasta meal 
intake absorption are considered.
Large Meal Absorption
The simulation results focused on the classical meal absorption curve of Lehmann and Deutsch;30 however, in order 
to test the robustness of the developed algorithm, we referred to large meal absorptions. In normal individuals, it is 
known that plasma glucose is restored to premeal basal levels in approximately 120 min for a normal meal (~1 g glucose/
kg body weight), but for a very large meal (~4.5 g glucose/kg body weight), this period is up to 360 min.33 The latter 
situation can be considered the worst case of meal intakes.
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In order to test the effect of large meal intake (based on theoretical models of absorption34), the concentration of 
glucose absorption rate (normalized by distribution volume) can be considered to follow a Weibull curve (Figure 5):
g = p3te–t,                                                                 (3)
where t = tp1
⎛
⎜
⎝
⎞
⎟
⎠
p2
.
Observing the role of parameters p1, p2 and p3, it can be seen that
• p1 corresponds to the input scaling, in other words, it scales the curve along the horizontal axis;
• p2 determines the shape of the curve since it can be interpreted as a time constant of the system; and
• p3 scales the curve along the vertical axis.
Therefore, the amount of the glucose input can be taken into account by p3, whereas patient variability can be modeled 
by p2.
Simulation results of the robust controller on the considered large meal absorption profile are presented in Figure 6. 
It can be seen again that simulation results are better with the original nonlinear system than with the LPV model, 
while the insulin output is again the same for the two considered models.
Figure 5. Large meal33 and Weibull approximation of exogenous 
glucose absorption.
Figure 6. The LPV-based robust controller simulation results for large 
meal absorption profile taken from Korach-André and coauthors.33
In conclusion, it can be mentioned that, after tuning, no information about meal occurrence is needed for the designed 
robust controller as long as meal amount does not exceed the expected maximum of the corresponding polytopic region.25
Virtual Patient Generation
To start virtual patient generation in the case of the modified Sorensen model, the same sensitivity analysis was used 
as reported by Parker and coauthors.12 The complexity, however, was a disadvantage regarding the identification 
method since the problem was numerically badly conditioned and had various local optima; furthermore, the stability 
of the model was difficult to assure or even to determine.25 Two T1DM patients’ 1-week-long real data were collected 
to perform the first tests: patient 1 was a 17-year-old boy (he has used an insulin pump for half a year and has an 
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active lifestyle and good compliance), while patient 2 was a 43-year-old woman (she has used an insulin pump for 
3 years and is characterized with moderate compliance). Both patients used a Medtronic Paradigm 522 pump and 
followed their usual lifestyle. The only control in the system was that their daily plan was discussed a day before by 
their doctor, and the following day, the doctor checked if corresponding data were registered correctly (CHO intake 
and physical activity); consequently, the patients did not follow specific meal protocol.
Every CHO amount was modeled in the system as a large meal with a Weibull curve absorption profile presented in 
Equation (3).
Figure 7 presents results of 3 of 7 days total  for patient 1 using the large absorption scenario (worst-case test). 
In this case, every CHO intake of the patient was adjusted as a large meal absorption presented in Equation (3)
Figure 8 presents results of 3 of 7 days total for patient 2 using the large absorption scenario (worst-case test). 
In this case, every CHO intake of the patient was again adjusted as a large meal absorption presented in Equation (3).
Figure 7. Comparison of robust controller output (solid) and collected 
CGM data (dashed) using large meal absorption scenario in case 
of patient 1. The dots represent the real fingertip measurements. 
The middle figure shows the absorption profiles of CHO intakes 
considered as large meal absorptions. The lower figure represents the 
insulin control input.
Figure 8. Comparison of robust controller output (solid) and collected 
CGM data (dashed) using large meal absorption scenario in case 
of patient 2. The dots represent the real fingertip measurements. 
The middle figure shows the absorption profiles of CHO intakes 
considered as large meal absorptions. The lower figure represents the 
insulin control input.
Discussion
Results of both patients (Figures 7 and 8) show that the output of the controller fit the blood glucose level almost all 
the time in the normal 3.9–7.8 mmol/liter (70–140 mg/dl) range, and a hypoglycemic episode was avoided. In the case of 
the control input, only the controller’s calculated input (insulin) is presented.
It can be seen that the patients’ physiology is followed, but variation of the blood glucose levels is much lower. Due to 
worst-case design and uncertainties taken into account and included in the control design, hypoglycemic events were 
avoided and hyperglycemic episodes are lower in most of the cases than those exhibited in the patients’ real data.
Investigating the control algorithm (without any recalibration) on the model presented by Kovács and coauthors,25 
two remarks should be highlighted. First, it can be seen that the blood glucose level could be again stabilized in a 
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better range than the real data of the patients, and also, hypoglycemia events can be avoided. Hence, the presented 
preliminary results demonstrate the robustness capability of the developed algorithm; however, more simulation 
results are required.
Investigating the individualized control strategies (e.g., MPC) presented in the literature, it can be concluded that 
individual protocols have given better results per patient than the developed robust controller. However, in our case, 
this is much more an advantage than a disadvantage. It is known that MPC strategies have better results in the case of 
individual control problems.14,35,36 However, robustness is much harder to guarantee in these cases. In contrast, modern 
robust control could give a generalized solution, but examined on individual cases, it leaves space for improvement.
Conclusions
This article summarized a nonlinear model-based LPV robust controller and proved by preliminary results its 
applicability and robustness with different scenarios taken into account. Hence, it has the potential to handle patient 
groups and—in this way—efficiently support and complement individualized control (e.g., MPC-based) protocols.
This article is the first part of a series of three publications (presenting Hungarian AP research results). The second 
paper aims to deal with in silico tests, while the third paper should give a summary of the work done.
Furthermore, we plan to extend the robust framework with hard constraints regarding physical activity and stress and 
test the results on other patients’ data as well. We also plan to investigate model-free approaches37 by implementing 
the same controller structure to different models, preferably based on the ones used most frequently in AP research 
by the international community.13,14 Finally, the capabilities of these controllers will be tested on either the modified 
Sorensen model or any model not used for the controller design. Our further aim is to test our results on the 
Food and Drug Administration-approved simulator38 as well and to combine our framework with individualized 
control protocols.
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